Association between butyrylcholinesterase K variant and the Alzheimer type neuropathological changes in apolipoprotein E ε4 carriers older than 75 years

November 1999
Journal of Neurology, Neurosurgery & Psychiatry;Nov1999, p693
Academic Journal
No abstract available.


Related Articles

  • Butyrylcholinesterase K and Apolipoprotein ε4 Affect Cortical Thickness and Neuropsychiatric Symptoms in Alzheimerµs Disease. Yoo, Hye B.; Lee, Hae W.; Sue Shin; Sun-Won Park; Choi, Jung S.; Jung, Hee Y.; Jungho Cha; Jong-Min Lee; Jun-Young Lee // Current Alzheimer Research;Feb2014, Vol. 11 Issue 2, p137 

    Two major genotypes are known to affect the development and progression of Alzheimer's disease (AD) and its response to cholinesterase inhibitors: the apolipoprotein E (ApoE) and butyrylcholinesterase genes (BChE). This study analyzed the effects of the BChE and ApoE genotypes on the cortical...

  • Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease. Tilley, Louise; Morgan, Kevin; Grainger, Joe; Marsters, Peter; Morgan, Linda; Lowe, James; Xuereb, John; Wischik, Charles; Harrington, Charles; Kalsheker, Noor // European Journal of Human Genetics;Sep99, Vol. 7 Issue 6, p659 

    The ε4 allele of the apolipoprotein E gene (APOE) is a major risk factor for late-onset Alzheimer's disease (LOAD) but is neither necessary nor sufficient to cause the disease. In this study, we investigated polymorphisms in the presenilin-1 (PS-1), and butyrylcholinesterase (BChE) genes,...

  • Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation. Holmes, C.; Ballard, C.; Lehmann, D.; Smith, A. David; Beaumont, H.; Day, I. N.; Khan, M. Nadeem; Lovestone, S.; McCulley, M.; Morris, C. M.; Munoz, D. G.; O'Brien, K.; Russ, C.; Del Ser, T.; Warden, D.; David Smith, A; Nadeem Khan, M // Journal of Neurology, Neurosurgery & Psychiatry;May2005, Vol. 76 Issue 5, p640 

    Objective: To determine whether individuals with Alzheimer's disease (AD) and the K variant allele of butyrylcholinesterase have a slower rate of cognitive decline than those without the K variant allele of butyrylcholinesterase.Method: The cognitive status of 339...

  • Neither the butyrylcholinesterase K variant nor transferrin C2 variant confers a risk for Alzheimer's disease in Koreans. Kim, K. W.; Jhoo, J. H.; Lee, J. H.; Lee, K. U.; Lee, D. Y.; Youn, J. C.; Youn, J. Y.; Woo, J. I. // Journal of Neural Transmission;Oct2001, Vol. 108 Issue 10, p1159 

    Summary. To investigate the possible involvement of the butyrylcholinesterase (BCHE) K variant and transferrin (TF) C2 variant in the manifestation of Alzheimer's disease (AD), we analyzed the BCHE, TF and apolipoprotein E (APOE) genotypes of 164 sporadic AD patients and 239 normal elderly...

  • Apolipoprotein E allelotype is associated with neuropathological findings in Alzheimer's disease. Kumar, Neena; Liestøl, Knut; Løberg, Else; Reims, Henrik; Mæhlen, Jan // Virchows Archiv;Aug2015, Vol. 467 Issue 2, p225 

    In a consecutive hospital-based autopsy series, we examined the relationship between apolipoprotein E (apoE) and Alzheimer's disease (AD) and investigated the clinicopathological relationship in AD. The study population included 99 patients (mean age 81 years) with AD-related neuropathological...

  • Pharmacogenomics and the Treatment of Sporadic Alzheimer's Disease: A Decade of Progress. Poirier, Judes; Gauthier, Serge // Current Pharmacogenomics & Personalized Medicine;2008, Vol. 6 Issue 1, p63 

    Several lines of evidence indicate that apolipoprotein E (apoE) plays a central role in the brain's response to injury and neurodegeneration in the adult. The coordinated expression of apoE and several of its accessory proteins appears to regulate the transport and internalization of cholesterol...

  • The APOE É›4 allele modulates brain white matter integrity in healthy adults. Heise, V.; Filippini, N.; Ebmeier, K. P.; Mackay, C. E. // Molecular Psychiatry;Sep2011, Vol. 16 Issue 9, p908 

    The Apolipoprotein E (APOE) ɛ4 allele is the best-established genetic risk factor for sporadic Alzheimer's disease, and is also associated with structural gray matter and functional brain changes in healthy young, middle-aged and elderly subjects. Because APOE is implicated in brain...

  • BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors. Chianella, Caterina; Gragnaniello, Daniela; Maisano Delser, Pierpaolo; Visentini, Maria; Sette, Elisabetta; Tola, Maria; Barbujani, Guido; Fuselli, Silvia // European Journal of Clinical Pharmacology;Nov2011, Vol. 67 Issue 11, p1147 

    Purpose: Cholinesterase inhibitors are commonly prescribed to patients with Alzheimer's disease (AD) to enhance cholinergic neurotransmission. Differential response to these treatments has been observed, and claims have been made that individual genetic variants may influence the pharmacokinetic...

  • Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer’s disease. Shinohara, Mitsuru; Fujioka, Shinsuke; Murray, Melissa E.; Wojtas, Aleksandra; Baker, Matthew; Rovelet-Lecrux, Anne; Rademakers, Rosa; Das, Pritam; Parisi, Joseph E.; Graff-Radford, Neill R.; Petersen, Ronald C.; Dickson, Dennis W.; Bu, Guojun // Brain: A Journal of Neurology;May2014, Vol. 137 Issue 5, p1533 

    Sporadic and familial Alzheimer’s disease differ in region-specific amyloid-β accumulation, pattern of neurodegeneration, and symptoms. Shinohara et al. quantify amyloid-β, tau and related molecules and reveal a synapse-associated pattern of amyloid-β42 in sporadic disease, and...

  • Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease. Lehmann, Donald J.; Nagy, Zsuzsanna; Litchfield, Suzanne; Cortina Borja, Mario; Smith, A. David // Human Genetics;Apr2000, Vol. 106 Issue 4, p447 

    In confirmed late-onset (>65 years) Alzheimer's disease, we found a greater load, both of overall neuritic plaques and of cholinesterase-positive neuritic plaques, in the temporal cortex of carriers of the butyrylcholinesterase K variant (BCHE-K) aged <80 years than of all other patients. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics